Rapid Antimicrobial Susceptibility Testing



 

Antimicrobial susceptibility testing (AST) results have a significant impact when managing patients with serious infections. Recent developments in identification tools can now identify microbes with unprecedented speed, but phenotypic susceptibility testing has lagged behind. New phenotypic AST systems are being introduced with the promise of improving current molecular tests by rapidly measuring inhibition of growth across panels of antibiotics. In this presentation, we will explore the technology, performance, and impact on patient care of these new, rapid AST methods.

Originally published on January 30, 2020


Lecture Presenter

Mark Fisher, PhD, D(ABMM)

Mark Fisher, PhD, D(ABMM)

Medical Director, Bacteriology; Medical Director, Special Microbiology, Antimicrobial Susceptibility Testing
ARUP Laboratories
Associate Professor of Clinical Pathology
University of Utah School of Medicine

Dr. Fisher is an associate professor of pathology at the University of Utah School of Medicine. He obtained a PhD in microbiology and molecular genetics from Emory University and a master of science in microbiology from Idaho State University. Dr. Fisher subsequently completed fellowships in microbial pathogenesis at the Rocky Mountain Laboratories (NIH) and in medical microbiology at the University of Utah. He is board certified in medical microbiology, and his research interests include microbial pathogenesis and transmission of vector borne pathogens.


Objectives

After this presentation, participants will be able to:

  • Discuss current rapid AST methods
  • Evaluate clinical impact of rapid AST
  • Assess future rapid AST technologies

Sponsored by:

University of Utah School of Medicine, Department of Pathology, and ARUP Laboratories